Efficacy and safety of carboplatin+etoposide regimens combined with abiraterone+prednisone in patients with metastatic castration-resistant prostate cancer
10.12354/j.issn.1000-8179.2024.20240262
- VernacularTitle:卡铂+依托泊苷联合阿比特龙+强的松治疗转移性去势抵抗性前列腺患者的疗效和安全性
- Author:
Xie CHENGMING
1
;
Hu LINJUN
;
Tian JUN
;
Bai HONGSONG
;
Shan XINGLI
;
Chen YONGHAI
;
Ning HOUSHAN
;
Xing SIJIA
;
Ni DONGLIN
Author Information
1. 北京市朝阳区桓兴肿瘤医院泌尿科(北京市 100020)
- Keywords:
metastatic castration-resistant prostate cancer(mCRPC);
chemotherapy;
novel hormone therapy(NHT);
post-treatment progression
- From:
Chinese Journal of Clinical Oncology
2024;51(10):510-513
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and toxicities of carboplatin+etoposide(CE)regimens combined with abiraterone+prednisone(AAP)in patients with metastatic castration-resistant prostate cancer(mCRPC)after progression with docetaxel+prednisone(DP)regimens chemotherapy and novel hormone therapy(NHT).Methods:Retrospective analysis of mCRPC treated with DP regimens chemotherapy and/or NHT after progression,received CE regimens with AAP every 3 weeks for one cycle×6 cycles.The outcome were prostate specific an-tigen(PSA)response rate,time to PSA progression(TTPP),radiographic progression-free survival(rPFS),30%reduction in PSA,90%reduc-tion in PSA,the objective response remission rate and overall survival(OS).Results:From March 2019 to February 2024,37 eligible mCRPC patients were admitted to Cancer Hospital of Huanxing Chaoyang District Beijing and National Cancer Center/National Cancer Clinical Re-search Center/Cancer Hospital.After progression,CE regimens combined with AAP regimens was used for treatment.The median follow-up was 12.0(3.0-57.0)months.The median treatment cycle was 4 cycles.The PSA response rate was 42.1%.The median TTPP was 4.0 months;the median rPFS was 8.9 months and the median OS was 15.0 months.The objective remission rate was 24.3%,the proportion of 30%de-crease in PSA was 59.5%,and the proportion of 90%decrease in PSA was 16.2%.As for treatment side effects,10 cases had grade 3 or higher adverse reactions.Conclusions:CE regimens combined with AAP for mCRPC patients who failed DP regimens chemotherapy and/or NHT initially showed good clinical efficacy and tolerability.Additional sample size and follow-up time are needed to further validate the effic-acy.
